Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic
  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Exploring Expanded Application of ODF Screening Tests

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) is taking a close look at a significant potential market for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. According to the company, some buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been linked to serious oral health problems that necessitate medical intervention. XPhyto’s proprietary ODF biosensor screening tests may have the ability to detect buprenorphine-related dental problems. A recent Drug Safety Communication (“DSC”) issued by the U.S. Food and Drug Administration (“FDA”) warned about dental problems, including tooth decay, cavities, oral infection and loss of teeth, associated with buprenorphine medicines that dissolve in the mouth to treat opioid use disorder and pain. Despite those issues, the FDA recommended the continued use of these medications because the benefits outweigh the risks and oral care can assist in solving the side effects. XPhyto’s proprietary ODF biosensor development portfolio includes multiple oral health products, and the company is now investigating the potential application of one or more of these oral health biosensor screening tests to detect buprenorphine-related dental problems. The company plans to provide updates on its oral health and infectious disease screening test programs in the coming weeks.

To view the full press release, visit https://ibn.fm/gETOZ

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.